To access this material please log in or register

Register Authorize

New loop diuretics in treatment of arterial hypertension

Gendlin G. E., Melekhov A. V., Ryazantseva E. E.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: hyperpiesis, diuretics, treatment

DOI: 10.18087/rhj.2013.2.1745

According to the modern guidelines, diuretics place an important role in complex antihypertensive treatment. Torasemid is the safest and most effective diuretics, which not only lacks disadvantages of other drugs of this group (electrolytic disorders, excessive and frequent urination), but also has additional advantages: antialdosterone, antifibrotic, vasodilative effects. For this reason, torasemid can be reasonably considered as a first-choice medicine in treatment of hypertension and others CVDs, which require administration of diuretic therapy.
  1. Четвертый пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардио­васкулярная терапия и профилактика. 2010;3 (3) 105–120.
  2. Машковский, М. Д. Лекарственные средства: пособие для врачей. – 16‑е изд., пеpеpаб., испр. и доп. – М.: Новая Волна, 2011. – 1216 с.
  3. Chaturvedi S. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): is it really practical? Natl Med J India. 2004;17 (4):227.
  4. Biddle TL, Yu PN. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction. Am J Cardiol. 1979;43 (1):86–90.
  5. Ghys A, Denef J, Delarge J, Georges A. Renal effects of the high ceiling diuretic torasemide in rats and dogs. Arzneimittelforschung. 1985;35 (10):1527–1531.
  6. Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol. 1986;31 (Suppl): 35–42.
  7. Broekhuysen J, Deger F, Douchamps J et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31 (Suppl): 29–34.
  8. Herchuelz, A., et al., Comparative pharmacodynamics of torasemide and furosemide in patients with oedema. Arzneimittelforschung, 1988. 38 (1A): p. 180–183.
  9. Reyes AJ. Formal comparison of the antihypertensive effects of torasemide and other diuretics by the Montevideo mathematical model. Arzneimittelforschung. 1988;38 (1A): 194–199.
  10. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205 (2):145–150.
  11. Yamato M, Sasaki T, Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390.
  12. Dodion L, Willems JL. Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency. Eur J Clin Pharmacol. 1986;31 (Suppl): 49–51.
  13. Brater DC, Rudy DR, Voelker JR et al. Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency – preliminary evaluation. Cardiovasc Drugs Ther. 1993;7 (Suppl 1):69–73.
  14. Wittig T, Medert G. [Torasemide in patients with chronic heart failure. Results of clinical administration in general practice]. Fortschr Med. 1996;114 (3):24–28.
  15. Kasama S, Toyama T, Hatori T et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92 (10):1434–1440.
  16. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50 (9):859–867.
  17. Aronow WS, Fleg JL, Pepine CJ et al. ACCF / AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011;5 (4):259–352.
  18. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens. 2002;15 (S3):113A-114A.
  19. Temelkova-Kurktschiev TS, Kurktschiev DP, Vladimirova-Kitova LG et al. Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies. Folia Med (Plovdiv). 2009;51 (1):34–41.
  20. Coca A, Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens. 2001;14 (S1):116A.
  21. Spannheimer, A.,Spannheimer A, Müller K, Falkenstein P et al. [Long-term diuretic treatment in heart failure: are there differen­ces between furosemide and torasemide?]. Praxis (Bern 1994). 2002;91 (37):1467–1475.
  22. Stroupe KT, Forthofer MM, Brater DC. Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17 (5):429–440.
  23. Barbanoj MJ, Ballester MR, Antonijoan RM et al. Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers. Fundam Clin Pharmacol. 2009;23 (1):115–125.
  24. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. Torasemide-PR in Hypertension Clinical Trial Investigators Group Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther. 2008;26 (2):91–100.
  25. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  26. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  27. Hunt SA, Abraham WT, Chin MH et al. ACC / AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112 (12):e154–235.
Gendlin G. E., Melekhov A. V., Ryazantseva E. E. New loop diuretics in treatment of arterial hypertension. Russian Heart Journal. 2013;12(2):119-122

To access this material please log in or register

Register Authorize
Ru En